Improving healthcare for patients with HIV, tuberculosis and hepatitis C in eastern Europe: a review of current challenges and important next steps.

HIV-positive persons; MEDICAL quality control; ONLINE information services; HEALTH services accessibility; SYSTEMATIC reviews; HEPATITIS C; MEDICAL care; TUBERCULOSIS; QUALITY assurance; MEDLINE

Objectives: In some eastern European countries, serious challenges exist to meet the HIV‐, tuberculosis (TB)‐ and hepatitis‐related target of the United Nations Sustainable Development Goals. Some of the highest incidence rates for HIV and the highest proportion of multi‐drug‐resistant (MDR) tuberculosis worldwide are found in the region. The purpose of this article is to review the challenges and important next steps to improve healthcare for people living with TB, HIV and hepatitis C (HCV) in eastern Europe. Methods: References for this narrative review were identified through systematic searches of PubMed using pre‐idientified key word for articles published in English from January 2000 to August 2020. After screening of titles and abstracts 37 articles were identified as relevant for this review. Thirty‐eight further articles and sources were identified through searches in the authors' personal files and in Google Scholar. Results: Up to 50% of HIV/MDR‐TB‐coinfected individuals in the region die within 2 years of treatment initiation. Antiretroviral therapy (ART) coverage for people living with HIV (PLHIV) and the proportion virological suppressed are far below the UNAIDS 90% targets. In theory, access to various diagnostic tests and treatment of drug‐resistant TB exists, but real‐life data point towards inadequate testing and treatment. New treatments could provide elimination of viral HCV in high‐risk populations but few countries have national programmes. Conclusion: Some eastern European countries face serious challenges to achieve the sustainable development goal‐related target of 3.3 by 2030, among others, to end the epidemics of AIDS and tuberculosis. Better integration of healthcare systems, standardization of health care, unrestricted substitution therapy for all people who inject drugs, widespread access to drug susceptibility testing, affordable medicines and a sufficiently sized, well‐trained health workforce could address some of those challenges. [ABSTRACT FROM AUTHOR]